Creative Medical Technology Holdings Announces Next Milestone Achievements in ImmCelz® Platform Development

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"Advancements May Result in Ability to Treat a Broader Patient Population with Immune Disorders\nPHOENIX, May 22, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (\"Creative Medical Technology\" or the \"Company\") (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today announced significant advances in the ongoing development of its ImmCelz® (CELZ-100) platform, the Company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders.\n\n \n \n \n \n \n \n\n \nThese advances support the Company's prior work in this area and confirm that the use of fewer donor cells can lower production costs while producing a more potent and efficacious final product.\nIn particular, independent studies confirmed:\nThat the ImmCelz® (CELZ-100) platform required 75% fewer donor patient cells compared to industry standard;That the purity of the final ImmCelz® (CELZ-100) product was greater than 95% compared to the industry standard of greater than 80%;That ImmCelz® (CELZ-100) demonstrated a greater than 200% reduction in functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells; andThe ability to verify repeated potency of the final ImmCelz®(CELZ-100) product.All experiments were independently conducted and validated on selected human donor patient cells for accuracy and reproducibility.\n\"We are thrilled to have achieved these important milestones in the development of our ImmCelz® (CELZ-100) platform, particularly the purity and functionality of the cells while substantially reducing the production costs,\" said Timothy Warbington, CEO of Creative Medical Technology Holdings. \"We continue to be optimistic in the development of the ImmCelz® (CELZ-100) platform.\"\n\"We believe that our ability to reduce the number of donor patient cells by 75% to obtain a better product for patients is a potential game changer in immunotherapy,\" said Courtney Bartlett, DNP – Director of Clinical Operations. \"We now will be able to reach a greater number of potentially sicker patients who previously may not have been eligible for an immunotherapy due to the incre...

More updates from Creative Medical Technology Holdings, Inc.